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Abstract 
Several key topics in solubility measurement and interpretation are briefly summarized and illustrated with 
case studies drawing on published solubility determinations as a function of pH. Featured are examples of 
ionizable molecules that exhibit solubility-pH curve distortion from that predicted by the traditionally used 
Henderson-Hasselbalch equation and possible interpretations for these distortions are provided. The scope 
is not exhaustive; rather it is focused on detailed descriptions of a few cases. Topics discussed are 
limitations of kinetic solubility, ‘brick-dust and grease-balls,’ applications of simulated and human intestinal 
fluids, supersaturation and the relevance of pre-nucleation clusters and sub-micellar aggregates in the 
formation of solids, drug-buffer/excipient complexation, hydrotropic solubilization, acid-base 
‘supersolubilization,’ cocrystal route to supersaturation, as well as data quality assessment and solubility 
prediction. The goal is to highlight principles of solution equilibria – graphically more than mathematically 
– that could invite better assay design, to result in improved quality of measurements, and to impart a 
deeper understanding of the underlying solution chemistry in suspensions of drug solids. The value of solid 
state characterizations is stressed but not covered explicitly in this mini-review. 
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Introduction 
For many oral drugs, the rate-limiting step in intestinal absorption is dictated by the kinetics of 
dissolution of the active pharmaceutical ingredient from the solid form. The dissolution rate is a function of 
a number of factors, foremost being the aqueous solubility of the drug, which, for ionizable molecules, can 
be affected by the pH of the medium [1]. Also, depending on the drug that has been introduced, the 
dissolution may overshoot the saturation concentration and produce a supersaturated solution. The 
supersaturation is typically achieved when the API is introduced in its amorphous form or in a charged form 
as a salt. In such a supersaturated solution, drug molecules may self-associate as sub-micellar 
aggregates/clusters, particularly if they are surface-active or polarizable. For bases introduced as drug salts 
into an alkaline-pH solution, the charged drug in the supersaturated solution can disproportionate into oil 
or undergo precipitation into a new amorphous solid, with which charged water-soluble aggregates may co-
exist. Given enough time, the oil or amorphous solid (and any other type of aggregates) are expected to 
undergo phase transformation into a thermodynamically more stable crystalline solid, the steps governed 
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by kinetics of nucleation and crystal growth. For drugs that are practically insoluble in water, dissolution 
and re-crystallization can be particularly complicated kinetic processes occurring at different interfaces of, 
e.g., undissolved API or colloidal structures composed of excipients. Aggregation and recrystallization are to 
date not fully understood and hence may be difficult to predict. About two-thirds of the compounds in the 
drug discovery pipeline are very poorly soluble in water, and therefore show low and/or erratic intestinal 
absorption. To increase solubility (and thus absorption), oral drugs are often formulated as salts. However, 
there are numerous other strategies which have been successfully implemented [2,3]. 
Several aspects of the above complexity are summarized in this mini-review. It is intended to serve as 
prologue or accompaniment to an upcoming session on solubility at the IAPC-8 meeting in Split, Croatia, 9-
11 September 2019, to be co-chaired by the authors. Since 2009, the International Association of Physical 
Chemists (IAPC, www.iapchem.org) series of symposia maintained extensive coverage of the topic of 
solubility measurement, both from solid state and solution perspectives. At the 2015 IAPC-4 meeting, the 
“Thermodynamic Solubility Measurement of Practically Insoluble Ionizable Drugs - Case Studies & Suggested 
Method Improvements” special session resulted in a ‘white paper’ publication drawing on expert consensus 
thoughts of researchers from six countries (Hungary, Russia, Serbia, Spain, Sweden, United States) [4]. At 
the 2017 IAPC-6 meeting, the “Pharmaceutical Cocrystals -Physicochemical Properties and Formulations” 
special session included presentations from internationally-recognized experts in cocrystal solubility-pH 
measurement. Several publications on the topic emerged out of the meeting. It is anticipated that future 
sessions will continue to cover solubility methods and strategies, to critically address the different needs in 
pharmaceutical research, spanning from drug discovery to drug development. 
Brief survey of topics in solubility 
Several key topics are briefly summarized below and are illustrated with case studies drawing on 
solubility determinations as a function of pH. Significant effort was made to find useful examples from the 
published literature which illustrated principles of solution equilibria. The coverage is not exhaustive, but is 
considerable in some cases, to address issues of measurement and interpretation of pH dependency in 
solubility profiles. The value of solid state characterizations is stressed but not covered explicitly in this 
mini-review. 
Kinetic or thermodynamic?  
It’s been more than two decades since Lipinski’s Rule of 5 was published [5], addressing the problems of 
poorly soluble compounds. High-throughput microtitre plate methods for determining ‘kinetic’ solubility 
based on turbidity detection became very popular. Usually, a DMSO solution of the drug is added gradually 
to an aqueous buffer, until the first signs of solid formation are detected. The resultant precipitate is most 
often amorphous, up to a hundred times more soluble than that measured by conventional 
‘thermodynamic’ (slow-to-medium throughput) methods. Pharmaceutical company databases mostly 
contain kinetic values. Gradually, it became evident that placing heavy focus on using kinetic data could 
drive the lead-to-candidate optimization process in the wrong direction: towards making more amorphous-
tending compounds, generating problems later on in development [6-8]. Limitations of these early methods 
can lead to misconceptions and promote the lack of understanding of solubility data [7]. One way to 
mitigate some of the development-stage risks is to implement ‘miniaturized’ solubility methods (which can 
produce values closer to those of shake-flask thermodynamic measurements), brought forward alongside 
potency assessments [9]. This is not necessarily easy to do due to the inherently higher costs of 
measurement, particularly when directed at large compound libraries [10]. Also, such implementation 
requires some understanding of solubility-pH relationships.  
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Brick dust and grease balls 
Low-soluble compounds are often colloquially classified as ‘brick dust’ or ‘grease balls’ [11]. The 
solubility of the former type is mainly limited by a strong crystal lattice, making it difficult for the compound 
to dissociate from the solid form. Such ‘brick dusts’ are high melting point crystalline solids (Tm > 200 °C) in 
which strong intermolecular bonds within the crystal lattice overcome the competing pull of solvation by 
water. In contrast, the ‘grease ball’ molecules are limited in their solubility by poor hydration. They typically 
have high octanol-water partition coefficients (log P > 3), and are hydrophobic compounds that form 
relatively low melting point solids. These compounds are unable to form strong bonds with the water 
molecules, and hence exhibit high log P [12]. Contemporary medicinal chemistry synthesizes compounds as 
insoluble grease balls rather than brick dust [8,12,13]. Traditional formulation strategies (excipients, 
solubilizing agents, cyclodextrins, amorphous dispersions, etc.) are likely to improve oral absorption of 
grease balls, more so than that of brick dust [12]. One may also speculate that many of the ‘brick dust’ 
molecules never reach the development stage because they are too problematic to work with in assays 
(e.g., pharmacological potency, toxicity and ADME properties). Hence, they are screened out early during 
the discovery stage. 
Solubility in simulated and human intestinal fluids 
A drug’s solubility and dissolution behavior can be investigated in human intestinal fluid (HIF), but such 
media are difficult to obtain since they require in vivo sampling of the fluid. HIF composition is also highly 
variable [14], both intra- and inter-individually, and it is relatively difficult to work with on the lab bench 
due to its low buffer capacity. While the variability is important to capture to understand and predict 
potential population effects, this complexity also makes it more suitable for later stage studies. The 
development of multiple simulated intestinal fluid (SIF) recipes (FaSSIF, FeSSIF, others) applicable to the 
early drug development stage has therefore evolved [15]. A recent study by Khadra et al. [16] applied a 
mathematically-rigorous design-of-experiment (DOE) statistical technique to investigate how equilibrium 
drug solubility can be influenced by seven typical SIF components (sodium taurocholate, lecithin, sodium 
phosphate, sodium chloride, pH, pancreatin and sodium oleate) within concentration ranges found in HIF. 
Poorly-soluble acids (naproxen, indomethacin, phenytoin, and piroxicam), bases (aprepitant, carvedilol, 
zafirlukast, tadalafil), and uncharged drugs (fenofibrate, griseofulvin, felodipine, probucol) were tested. 
With the exception of pancreatin, all of the factors individually had a significant influence on equilibrium 
solubility. Differences between acids, bases, and neutral drugs were evident; however, the study also 
pointed towards (as many other studies also have done) that responses to changes in a solvent, e.g., 
micellar fraction and composition, salt and pH, are often compound specific and there are no generalizing 
rules or one-size-fits-all solutions.  
Supersaturation, liquid-liquid phase separation, amorphous solid, oil-to-crystal transformations 
Buffers can affect the formation of drug aggregates (i.e., molecular clusters). As an example: citrate, 
succinate, phthalate increase surface activity of phenothiazines; acetate decreases it [17]. Certain surface 
active bases produce oil when the drug hydrochloride is converted to the free base in situ at pH > pHmax. For 
example, a 30 μM chlorpromazine hydrochloride solution at pH 9 becomes supersaturated, which then 
partly separates as oil, which is more soluble than the crystalline free base. In contrast, a 2-5 μM alkaline 
solution (pH 9-12) prepared from chlorpromazine free base showed no surface activity [17].  
Figure 1 shows log solubility-pH profiles of haloperidol free base at different temperatures and in 
different buffer media reported by several groups [18-21]. The dashed curves refer to the profiles 
calculated from the simple Henderson-Hasselbalch (HH) equation (not corrected for ionic strength or 
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dilution effects), using the independently-determined pKa values appropriate for the temperature. The solid 
curves are calculated using the refined constants from fitting the measured log S-pH data (filled circles) to 
the proposed equilibrium model, using the pDISOL-X program (in-ADME Research; www.in-
adme.com/pdisol_x.html). S0 refers to the thermodynamic intrinsic solubility in pure water of the 
uncharged form of the dissolved substance in equilibrium with the crystalline solid. Its value is indicated by 
the lowest value in the dashed curve, in the highly alkaline region. The supersaturation in the pHmax region 
noted in the case of chlorpromazine hydrochloride also occurs for the haloperidol mesylate salt (as 
illustrated in Figs. 3c,d in Ref. [4]). However, it does not occur for the haloperidol free base. Figures 1a,d do 
show deviations from the theoretical dashed curve (HH) in the alkaline region (pH > 7), where the 




Figure 1. Haloperidol (free base) log S-pH profiles, illustrating alkaline-region distortions from the shape 
expected from the Henderson-Hasselbalch equation (dashed blue line). The solid red lines are the best fit to 
the measured data, using the regression analysis program pDISOL-X [22]. See text for further elaboration. 
Several phenomena can account for such a behavior: (i) the neutral (but not the charged) species forms 
a supersaturated solution; (ii) stable water-soluble uncharged aggregates of haloperidol form; (iii) the 
added crystalline free base, soon after dissolution, re-precipitate into an amorphous solid phase; (iv) liquid-
liquid phase separation (LLPS) takes place, where oil forms as the second liquid phase, in addition to the 
aqueous phase; and (v) the free-base (but not the charged-form) drug forms a complex with a component 
of the buffer, thus elevating solubility. Overlapping contributions from the above effects may also play a 
role. 
Without a specific molecular model for the phenomenon of ‘supersaturation’ (i), it is not clear why the 
extent of distortions is different in each of the frames of Figure 1 (and also in Figs. 3b,c,e in Ref. [4]). Case 
Bergström and Avdeef  ADMET & DMPK 7(2) (2019) 88-105 
92  
(ii) – thermodynamically-stable aggregation reaction – is not supported by the data, since the distortion is 
different in each of the frames. Cases (iii) and (iv) – amorphous solid and oil, resp. – are possible 
explanations for the distortion. Figure 1c, based on a 48-h equilibration time, shows no distortion in the 
alkaline region. It could be that the amorphous solid or oil have essentially converted into the 
thermodynamically most stable crystalline form by then, but not entirely during the 24-h equilibration in 
Figures 1a,d. The extent of distortion in Figure 1a, compared to Figure 1d, could be indicative of a possible 
role for drug-phosphate complex formation (v), since 0.15 M phosphate constituted the medium in Figure 
1a, but no buffers were in added in Figure 1d. 
It is evident from the above examples that solid state characterization would be needed to help decide 
on the most likely mechanism behind the observed distortions in Figure 1. Changing buffer types in the 
medium and selecting different equilibration-time approaches [4] would add further insight into the 
mechanistic basis for the shape distortions in Figure 1.  
It is worth noting that a comprehensive analysis of each of the log S-pH sets in Figure 1 (e.g., mass action 
model using all relevant chemical equilibria [22]) yields very similar log S0 values, showing systematic 
temperature dependence. Based on van’t Hoff analysis (e.g., Eq. (3) in Ref. [23]), the intercept value of log 
S0
25 at 25 °C is -5.78 ±0.02 and the slope value (enthalpy of solution), ΔHsol
o = 29 ± 6 kJ/mol. Based on the 
analysis of ten different published studies, the interlaboratory mean value for haloperidol is log S0
25= -5.71 
± 0.17 (0.73 μg/mL) for haloperidol [24]. The above 0.17 log unit standard deviation is precisely the value 
obtained in the averaging of 870 molecules whose solubility was reported in two or more studies, as 
described below.  
A common practice in the literature is to report the measured solubility near pH = pKa +/- 2 (for 
bases/acids, resp.) as the intrinsic value. The above examples suggests that caution is warranted for such a 
procedure: from Figures 1a,c,d, the mean value would be -5.07 ±0.82 (3.2 ±16 μg/mL), which would not 
represent the realistic accuracy of the underlying data. A common perception is that reproducibility in 
solubility measurements is typically not better than 0.7 log unit [25]. The haloperidol example suggests that 
better reproducibility can be achieved if published data are critically analyzed. The diclofenac example 
below will further elaborate this.  
   
 
Figure 2. Time sequence of liquid-liquid phase boundary transformation to crystalline phase at 0, 12, and 22 h 
[26]. Reprinted with permission from S. Veesler, L. Lafferrère, E. Garcia, C. Hoff, Phase transitions in 
supersaturated drug solution. Org. Proc. Res. Dev. 7 (2003) 983-989. Copyright 2003 American Chemical 
Society. 
The haloperidol discussion suggests that oil or amorphous solid forms in alkaline solutions. Generally, a 
supersaturated solution forms on initial dissolution. Such a solution can then spontaneously form two liquid 
phases (aqueous and oil), followed soon after by the appearance of crystals, as shown in the time sequence 
in Figure 2. Solute is transported from oil drops to crystal via the continuous phase in a solvent-mediated 
process in which the drops disappear as the crystal grows. After heating and cooling the crystals, LLPS is not 
regenerated, which further confirms that the LLPS is not a thermodynamically stable phase [26,27].  
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Amorphous and crystalline solids 
High-throughput solubility (HTS) methods, where DMSO solutions of the sample are added to buffer 
media, generally indicate a measure of the solubility of amorphous solids, with values greater than that 
indicated by crystalline solids. Amorphous phases are not thermodynamically stable and will undergo 
crystallization over time. Two amorphous phases may co-exist, or a transient oil phase may appear. An 
example of this is shown in Figure 3a for the case of terfenadine measurement using the μSOL method 
(Pion Inc.), with 1 %v/v DMSO in each of the 96-well buffer solutions [28]. The unfilled circles represent 
solubility values collected at the end of 23-h equilibration, and may suggest the presence of oil plus 
amorphous solid. (Alternatively, the ‘oil’ can be a more energetic amorphous solid co-precipitated with a 
more stable amorphous form.) The filled circles represent data collected at 68-h equilibration time, and 
may suggest the sole presence of the more stable amorphous solid. The apparent solubility at pH 11 is 
1.9 μg/mL for the shorter time. This value appears to be an order of magnitude greater than the analyzed 
value of 0.16 μg/mL, corresponding to the apparent intrinsic solubility of the more stable amorphous solid. 
Solid state characterizations were not reported for the above HTS measurements.  
  Figure 3. Terfenadine examples of oil/amorphous vs. crystalline phases solubility-pH profiles. (a) High-
throughput measurement [29]. Dotted curve is best-fit of 23-h equilibration data; solid curve is best-fit of 68-
h data. As a visual guide, the dashed curve is the HH curve calculated for crystalline terfenadine, based on the 
analysis of the data from Al Omari et al. (2007) [29], shown in the frame on the right. (b) Shake-flask 
thermodynamic measurements [29]. See text. 
The dashed curve in Figure 3a represents the thermodynamic solubility of the crystalline solid, 0.01 
μg/mL, based on the reported citrate-buffer data of Al Omari et al. [29]. The detailed analysis of the latter is 
shown in Figure 3b. The authors studied the solubility characteristics in 50 mM phosphate (unfilled circles) 
as well as citrate (filled circles) buffer. The 30 °C shake-flask data at 48-h equilibration appears to be of 
good quality. The phosphate-containing medium seems to indicate drug-buffer complexation for pH > pHmax 
(not seen in the citrate medium), as evidenced by the elevation in solubility above the dashed HH curve (pH 
7-8). The analysis suggests the equilibrium constant K = [Tf.TfH+.HPO4
2-]/[Tf][TfH+][HPO4
2-] = 10+8.96 M-2 for 
the monoanionic complex [24]. Between pHmax 6.7 and pH 8.3, the complex appears to shed one proton 
with increasing pH. In both the citrate and phosphate media, at pH below pHmax, two salts form between 
the drug and each buffer, consistent with the solid and dotted curves being below the HH dashed curve. 
The salt solubilities are quite similar for the citrate and phosphate systems. 
 Figure 4 shows a simpler example of a single amorphous-phase log S-pH profile of clotrimazole, 
measured at about 1-h equilibration time, compared to the corresponding crystalline phase profile, 
measured at 48-h equilibration [30]. In both cases, the curves nearly follow the pH dependence calculated 
by the Henderson-Hasselbalch equation (with a constant vertical displacement between the two), although 
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the amorphous curve shows a slight amount liquid-liquid separation above pH 7, as indicated by a small 





Figure 4. Clotrimazole example of 
amorphous vs. crystalline phase 






Pre-nucleation clusters (i.e. self-aggregates, sub-micelles, drug-buffer complexes) 
Although classical nucleation theory describes drug crystallization from a supersaturated aqueous solution, 
the understanding of the molecular basis underlying the nucleation steps is still incomplete [31]. The role of 
pre-nucleation clusters as solute precursors to nucleation and the link between the chemical speciation of 
homogeneous solutions and the process of phase separation of such clusters was reviewed by Gebauer et 
al. [31]. Sub-micellar pre-nucleation clusters form in many supersaturated solutions: calcium phosphate, 
amino acids – particularly glycine (see below), and many surface-active drug molecules, such as in 
phosphate-buffered solutions of chlorpromazine, acetylpromazine, verapamil, orphenadrine, hydralazine, 
pramoxine, and amiodarone, at pH slightly above that of pHmax [21,32]. The buffers in solution critically 
influence the stability of such clusters. The link between the clusters and the kinetics of crystallization is still 
work in progress, and could turn out to be a vibrant area for future investigations. It should also be noted 
that the loss of supersaturation may potentially start at the surface of the dissolving material that is 
provided in excess and not always from the supersaturated solution [33]. 
Solubility-pH profiles can indicate self-aggregation/cluster formations. In the pH region where the drug 
is charged and self-aggregation takes place, the slope in the log S-pH plot can reveal the order of 
aggregation [28]. Figure 5 shows three examples indicating formation of charged aggregates. In Figure 5a, 
brequinar appears to form a negatively-charged dimer at pH above 7, as indicated by a slope of +2 in the 
log S-pH plot; the corresponding sodium-drug salt precipitates above pH 9 [34]. Figure 5b shows the surface 
active molecule, 3-(4-heptylbenzoyl)-benzoic acid, apparently forming a negatively-charged octamer above 
pH 7, as indicated by the slope of +8 in the plot [35]. The authors proposed that anionic micelles formed, 
with a critical micelle concentration of about 0.3 mM. Figure 5c shows ciprofloxacin cation appearing to 
form a pentameric aggregate below pH 5 (slope = -5), overlapping with the formation of a phosphate salt at 
lower pH [36]. (The possibility of the formation of a soluble drug-phosphate complex near pH 5 has not 
been explored.) Most often, when such sub-micellar charged aggregates form, the distortion in the log S-pH 
curve is most prominent right below the pHmax for acids and right above the pHmax for bases, as indicated by 
the examples in Figure 5. 
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Figure 5. Examples of charged-species aggregation. 
(a) Brequinar appears to form a negatively-charged 
dimer above pH 7, as indicated by a slope of +2 in the 
log S-pH plot. Sodium-drug salt precipitates above pH 
9 [34]. (b) 3-(4-Heptyl-benzoyl)-benzoic acid appears 
to form an 8-monomer aggregate above pH 7, as 
indicated by the slope of +8 in the plot [35]. 
(c) Ciprofloxacin cation appears to form a pentameric 
aggregate below pH 6, as well as a phosphate salt for 
pH < pHmax [36]. The possibility of drug-phosphate 
complexation has not been ruled out. 
 
As discussed by Gebauer et al. [31], amino acids, particularly glycine, form sub-micellar pre-nucleation 
clusters. Figure 6 displays log S-pH profiles of six amino acids in buffer-free solutions, where pH was 
modified with HCl/NaOH [37-39]. Amino acids are highly soluble in water. Consequently, the ionic strength 
reaches nearly 5 M at the low-pH end of the profile in three of the cases. The pH < 3 and pH > 9 electrode 
readings may be significantly affected. The symmetrically U-shaped dashed curves in the figures were 
calculated using the simple HH equation, which does not factor in the effects of ionic strength. The solid 
curves, which are less symmetrical than the HH curves, are the results of regression analysis where effects 
of ionic strength were factored in [22]. The apparent log S0 values listed in the figures were calculated using 
only the data in the pH 4-8 interval, with the rest of the points assigned zero weights during the regression 
analysis. It can be seen that for pH < 3 and pH > 9, the measured points are notably below the solid curves. 
This is extremely so in the case of glycine in Figure 6b. Ordinarily, such distortion would suggest that the 
zwitterionic form of the molecules self-associate, thus raising the solubility [28]. However, it was not 
possible to fit the glycine data with an aggregation model that contained a single zwitterionic 
stoichiometry. At least several overlapping oligomers appear to be necessary to rationalize the nearly flat 
log S-pH profile of polymeric glycine. It may be that glycine forms a high-molecular weight polymer strands 
in saturated solutions, which persist across a broad swathe of pH. 
Hydrotropic solubilization via cluster formation  
In 1916, Neuberg [40] coined the term ‘hydrotrope’ for compounds that increase the solubility of 
sparingly-soluble organic substances, by interacting as ‘co-solubilizers.’ Usually, high concentrations of 
hydrotropes are necessary to increase solubility of the sparingly-soluble substance. Hydrotropes are 
thought to form aggregates in solution. Typical examples of hydrotropes include urea, nicotinamide, 
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sodium salicylate, and benzoates with a short alkyl chains, as these molecules can self-associate into small, 
sub-micellar clusters of 3-4 molecules [41]. A poorly-soluble molecule can be associated with these clusters 
and become solubilized in the process. Figure 7 shows an example of the hydrotropic solubilization of 
medazepam by salicylate anions [42]. It would be interesting to explore whether phosphate at high 




Figure 6. The solubility-pH profiles of amino acids showing departures from the ideal Henderson-Hasselbalch 
shape. The distortion is particularly extreme in the case of glycine. Since the data for pH < 4 and pH > 8 were 
not used in the regression analysis, the listed log S0 values are ‘apparent.’ The actual values may be lower, 
especially for glycine.  
 
 
Figure 7. Hydrotropic solubilization. Plot of 
the total concentration of medazepam in a 
saturated solution as a function of added 
sodium salicylate. The solubility data of 
Badwan et al. [42] were fit (using pDISOL-X) 
to an equilibrium model consisting of the 
drug forming a complex with four units of 
salicylate. ‘CAC’ is the abbreviation for critical 
aggregate concentration. 
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Supersolubilization and amorphous dispersions  
Parikh and Serajuddin [43] have developed a novel method of preparing solid dispersion by using 
acid-base interaction in water. Haloperidol was dissolved in concentrated aqueous solutions of a weak acid 
(e.g., malic, tartaric, or citric acid). Each weak acid was selected such that it would not form salts with the 
drug. The solubility of haloperidol exceeded 300 mg/g aqueous solution of malic acid. This was an 
extremely high aqueous solubility for haloperidol, considering that its intrinsic aqueous solubility in water 
as the free base is only 0.7 μg/mL, and the solubility of its salt forms (e.g., HCl, phosphate, maleate) is only 
about 1-5 mg/mL. Similar solubility enhancements were observed with itraconazole by the investigators. 
The extraordinary enhancement by acid-base interaction has been called ‘supersolubilization.’ On drying, 
the drug-containing material is a semisolid and sticky amorphous solid dispersion. Free-flowing powders 
that can be compressed into tablets are obtained by e.g., adsorbing drug solid dispersions with acids onto 
porous silica [44].  
Cocrystals enhancement of solubility  
Xanthines (e.g., caffeine, theophylline, theobromine) are known to form complexes with many 
pharmaceutical compounds. In a series of papers (1952-1954) Higuchi, Zuck and Lach [45] studied the 
xanthine molecular associations formed with simple organic molecules in saturated solutions. Weak 
caffeine-containing complexes were determined to form, in the decreasing order of stability: p-
hydroxybenzoic acid > benzocaine > butylparaben > p-aminobenzoic acid > salicylic acid > benzoic acid > 
aspirin > o-phthalic acid > benzoate > sulfathiazole > picric acid > sulfadiazine > suberic acid. Such 
complexes raised the solubility of the xanthine. These classic studies may bear relevance to the selection of 
‘coformers’ in cocrystal formation.  
A recent and still evolving formulation strategy to increase intestinal absorption is based on using 
cocrystals [46]. Cocrystals are materials composed of two or more different uncharged molecules (e.g., 
drug and ‘coformer’) within the same crystal lattice, which are associated by nonionic and noncovalent 
bonds. The altered solid state properties in cocrystals are generally expected to elevate the drug 
concentration in a similar way that drug salts do, as the drug is released in a dissolution process. The 
initially elevated concentration of the drug could lead to increased oral absorption of the drug. The analyses 
of solubility of salts and cocrystals are similar, since both are multi-component solids. Drug salts are 
characterized by a solubility product, Ksp
SALT= [drug][counterion], where the drug is charged. Cocrystals are 
similarly characterized by an equilibrium solubility product, Ksp
CC = [drug][coformer], but in contrast to salts, 
both the drug and the coformer are uncharged in the cocrystal. A method to predict Ksp
CC and the solubility 
enhancement of cocrystals, using an approach based on measured drug and coformer intrinsic solubility 
(S0
drug, S0
cof), combined with in silico H-bond descriptors, has been recently described [47,48]. The latter 
publications arose out of the IAPC-6 special session on cocrystal solubility. 
Figure 8 shows an example of a solubility profile as a function of pH for the indomethacin:saccharin 
cocrystal [49]. The points represent the measured total concentrations of the coformer saccharin (blue 
squares) and the drug indomethacin (red circles) under equilibrium conditions poised at 72-96 h, where 
both the cocrystal and the free-acid crystalline drug are indefinitely stable co-precipitates below pH 3.7. As 
the cocrystal partially dissolves below pH 3.7, it releases the solvated free drug at the concentration 
indicated by the SCC thick dashed line. This is the initial supersaturated concentration of the drug. It may not 
persist long, but while the drug is in the elevated concentration, its intestinal absorption may be 
significantly enhanced. The Henderson-Hasselbalch curve for indomethacin is indicated by the dashed red 
curve in the bottom of the drawing. The equilibrium concentration of indomethacin (solid red curve) is 
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above the dashed curve, with the difference peaking at about pH 3.7. This can be explained by the 
complexation of uncharged drug by the anionic saccharin. The effect diminishes above pH 5, since the 
concentration of the free drug diminishes due to ionization [47]. 
 
Figure 8. Plot of the total equilibrium 
concentrations of saccharin (upper solid line, 
blue), indomethacin (lower solid line, red), and 
of the maximum possible concentration of the 
solubilized indomethacin released from the 
cocrystal (thick dashed curve, SCC), as a function 
of pH. SCC is termed the ‘cocrystal solubility.’ 
The elevation of the SCC dashed curve above 
that of the indomethacin equilibrium solid red 
curve is viewed as the cocrystal ‘solubility 
advantage.’ The solubility product is no longer 
satisfied above pH 3.7, so the cocrystal no 




A comprehensive study of equilibrium solubility data quality based on the review of over 800 
publications was reported in 2015 [50]. Since then, more studies have been examined and a more robust 
estimate of the true interlaboratory reproducibility can be offered here. Improved estimates [4,50] of 
interlaboratory reproducibility are better revealed when solubility data are normalized for pH (to produce 
intrinsic solubility, S0, derived from water solubility, Sw, or multiple-pH measurements) and temperature (by 
transforming measurements performed in the range 10-50 °C to the standard value of 25 °C [23]). 
By way of an addendum to the 2015 study, the data-quality study now has 6355 intrinsic solubility 
entries in the Wiki-pS0 database (in-ADME Research), for 3014 different pharmaceutically-relevant 
molecules (solids at room temperature), drawing on the review of 1325 publications. Of all the entries, 
2144 are singletons, generally reported as Sw, but transformed to S0, and temperature adjusted (if needed) 
to 25 °C. These single-source results offer no direct indication of interlaboratory reproducibility. That 
indication comes from the 870 molecules for which solubility was reported from at least two different 
sources. Some molecules have been studied in surprisingly large number of different laboratories. For 
example, there were 34 different reports of the solubility of diclofenac found to date. Seventeen of these 
were measured at several different pH values, and are displayed in Figure 9. The next most-frequently 
studied molecules appear to be phenytoin, barbital, and ketoprofen with 30, 26, and 24 interlaboratory 
determinations, respectively. The average interlaboratory reproducibility, based on the curated 870 
replicated studies, has been determined to be 0.17 log unit, significantly lower than the interlaboratory 
reproducibility (~0.7 log unit) suggested in past studies [25]. Many factors can lead to the perception of 
poor quality of data. Comparing “raw” water solubilities (Sw) determined in unbuffered solutions can be 
problematic. For example, using inaccurate values of pKa to interpret the log S-pH data can lead to 
erroneous intrinsic solubility values. Ambient levels of carbon dioxide can significantly affect measured Sw 
values in the cases of sparingly soluble bases. So can unsuspected buffer-drug interactions, 
aggregate/micelle formations, presence of amorphous solids, supersaturated solutions, differences in the 
measurement temperature, and other experimental conditions. When an effort is made to critically factor 
in the possible sources of systematic error, the interlaboratory reproducibility is actually quite good. Still, 
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for some drug molecules, the intrinsic solubility is very uncertain, with standard deviation (SD) values 
exceeding 0.5 log unit. 











(M) SD n 
Clofazimine -9.05 0.93 5 Amiodarone -10.41 0.59 4 
Telmisartan -6.73 0.84 5 Saquinavir -5.92 0.58 3 
Buprenorphine -6.07 0.83 3 Quinine -3.06 0.57 7 
Mifepristone -5.22 0.75 4 Diflunisal -4.99 0.56 11 
Tamoxifen -7.52 0.72 7 Raloxifene -6.82 0.56 6 
Terfenadine -7.74 0.71 11 Diphenhydramine -3.21 0.55 4 
Sulfadimethoxine -3.74 0.70 3 Etoxadrol -1.96 0.55 3 
Curcumin -5.36 0.68 3 Didanosine -1.24 0.54 3 
Rifabutin -4.09 0.66 3 Danazol -6.10 0.52 10 
Iopanoic_Acid -5.49 0.66 3 Ezetimibe -4.94 0.51 4 
Pioglitazone -6.20 0.66 4 Chlorprothixene -5.99 0.51 6 
Amodiaquine -5.49 0.65 3 Bromocriptine -5.50 0.51 5 
Fentiazac -5.84 0.65 4 Miconazole -5.82 0.50 6 
Itraconazole -8.98 0.61 3 Omeprazole -3.70 0.50 3 
Procaine -2.30 0.60 3 Amantadine -2.19 0.50 3 
Bisoprolol -2.09 0.59 3 Thiabendazole -3.97 0.50 4 
a
 Calculated interlaboratory standard deviation. 
b
 Number of reported studies from different laboratories. 
In addressing data quality, it needs to be emphasized that standard conditions are essential: intrinsic 
solubility values are to be compared at the designated reference temperature of 25 °C. Mixing different 
types of solubility and not normalizing for temperature increase the apparent variance between different 
laboratory results, as noted in the haloperidol example (cf., Fig. 1). Although the realistic average 
interlaboratory reproducibility is relatively good, some low-soluble molecules are still problematic. Table 1 
lists the 32 compounds with the poorest reproducibility, drawing on sources where at least three different 
studies were reported. At the top of the list is clofazimine. Based on five reported values, the standard 
deviation is 0.93 log unit. Similarly, even though terfenadine solubility has been reported in eleven studies, 
its interlaboratory reproducibility at 0.71 is still high. Still, 32 out of 3014 molecules is a small fraction. The 
rest of the molecules are much better determined. Absent from the list in Table 1 is diclofenac, because its 
intrinsic solubility has a tight consensus value. Its averaged log S0
25 = -5.34 ±0.18, based on 34 published 
studies. The standard deviation is almost identical to the estimated interlaboratory reproducibility of 0.17. 
Thus, the diclofenac data from different laboratories offer an opportunity to examine issues that affect the 
quality of solubility measurements as a whole. That is, many of the possible challenges in the interpretation 
of data in the assessment of interlaboratory reproducibility can be revealed in the examination of 
diclofenac.  
It is evident that several different patterns of distortion occur in the diclofenac log S-pH profiles in Figure 
9 which cannot be predicted by the Henderson-Hasselbalch equation.  
One case, in Figure 9g, shows distortion similar to those shown in Figure 5, suggestive of charge-species 
aggregation reaction. The data can be rationalized by the formation of the hexameric diclofenac anion 
complex associated with three protonated 1-(2-hydroxyethyl)pyrrolidine cations. The points with the 
highest solubility (above the solid curve) appear to be indicative of supersaturation, and could not be 
explained by a simple equilibrium model.  
Distortions involving the free acid are evident in Figures 9f-o, which show elevated solubility in low-pH 
region, above that indicated by the dashed HH-calculated curve. These may indicate amorphous phase 
solubility (cf., Figure 1a,d). In some cases, the effect may be due to the limit of detection in the analytical 
technique used to measure the concentration of the practically-insoluble drug.  
Bergström and Avdeef  ADMET & DMPK 7(2) (2019) 88-105 
100  
Different solubility methods were used to collect the data in the figures. Figure 9a is based on HTS data 
(μSOL method) – there are many points in the plot, but they show considerable scatter. The rest of the 
examples are based on shake-flask measurement. Also, the temperature is not the same in the figure. Two 




















Figure 9. The diclofenac log S-pH measurements from 17 publications [28,51-64] reveal a plethora of effects 
that might lead to poor reproducibility in the determination of the intrinsic solubility. See text for details. 
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The rigorous regression analysis of the data in the figures, taking into account all relevant reactions in 
the equilibrium model [22], produced the intrinsic solubility values indicated in each frame of Figure 9. 
When these values are further transformed to a common reference temperature of 25 °C [23], the 
resultant mean value of the 17 cases turns out to be log S0
25 = -5.30 ±0.17 (1.6 ± 0.6 μg/mL). This mean is 
essentially the same as the one obtained from the averaging all 34 cited values, as noted above. The above 
standard deviation of the mean is identical to the interlaboratory reproducibility obtained from the analysis 
of 870 different molecules, and is quite a bit lower than the frequently cited uncertainty of ~0.7 log unit in 
solubility measurement, when comparing results from different laboratories [25]. 
How does such an impression of poor reproducibility in solubility measurement arise? As mentioned 
earlier, it is not uncommon to assume that the solubility 2 pH units below the pKa (for acids) or above the 
pKa (for bases) can be equated with the intrinsic solubility. Clearly, such an approximation would not be 
accurate in cases of the distortions found in Figures 9f-o (and those in Fig. 1a,d). The consequences of the 
above approximation can be illustrated by selecting the lowest solubility in each of the 17 cases and 
calculating the average: log S0
25 (approx.) = -5.01 ±0.59 (6.5 ± 8.5 μg/mL). The increased apparent standard 
deviation, 0.59, seems to be consistent with the ~0.7 value. 
Prediction of intrinsic solubility 
Many computational methods for predicting solubility have been described. These serve the important 
need to predict solubility risks during structural design in the early stages of drug discovery. The earlier 
methods used relatively small training sets (<1000 compounds), consisting of molecules (including liquids 
and gases) such as alcohols, pesticides, and herbicides. This limited the accuracy of the prediction of the 
solubility of drug solids. As more drug data became available for training the prediction models, methods 
improved. The ‘solubility challenge’ posed by Llinàs et al. [65,66] spurred fresh discussion about prediction 
efficacy and the quality of available data. The meta-analysis described in the preceding section examined 
factors related to data quality [50]. The study suggested two ways to improve quality of legacy 
measurement of equilibrium solubility, as discussed above. Methods based on shake-flask measurement as 
a function of pH (‘gold standard’), and two potentiometric methods (pSOL & CheqSol) can be 
recommended [4]. Predictions of solubility in simulated and aspirated intestinal fluids are exciting new 
topics in current research [67]. 
Summary and conclusions 
This review, albeit brief, points towards the complexity in understanding and predicting solubility-
related processes. These include dissolution, solubilization/aggregation, pH-, counterion- and buffer 
strength effects on solubility, and the impact of salt and cocrystal formation on dissolution, solubility and 
supersaturation. The debate around how consistent data we can achieve from solubility assays and to what 
extent the data can be used to model and predict, e.g., pH-dependence or solubilization tendencies in 
different solvents will continue. A platform for such a vibrant discussion which will spur new ideas is the 
upcoming IAPC-8 meeting where these topics will be further explored.  
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